Does aspirin prevent venous thromboembolism?

Diep, Robert; García, David

doi:10.1182/hematology.2020000150

Cited by 24 publications

(17 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings on one side implied the importance of a healthy diet, in particular a diet of high anti-inflammation potential, in development of VTE, which may facilitate the completeness of the primary prevention strategies for this disease, especially in smokers. On the other hand, our results might strengthen the evidence that the inflammation acts as one pathological basis for thrombosis, which hints the worth of future clinical research on anti-inflammation treatments, such as aspirin, for VTE prevention [31]. Our study also highlighted the link between certain foods, such as fruit and vegetables, wine, and French fries, and VTE risk, which could guide nutrition behaviors in general populations and clinical nutrition practice.…”

Section: Discussionsupporting

confidence: 78%

Anti-inflammatory diet and venous thromboembolism: Two prospective cohort studies

Yuan

Bruzelius

Damrauer

et al. 2021

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

Background and aims: Inflammation has been revealed to facilitate thrombogenesis and to increase the risk of venous thromboembolism (VTE). However, limited data are available on the association between the anti-inflammatory diet and incident VTE. We conducted a cohort analysis to examine this association and to further examine whether this association is modified by smoking status, a trigger of systemic inflammation. Methods and results: We used data from two cohorts including 81,507 middle-aged and older Swedish adults without previous VTE at baseline. An empirically validated anti-inflammatory diet index (AIDI), based on 12 foods with anti-inflammatory potential and 5 foods with proinflammatory potential, was employed to estimate the anti-inflammatory potential of diet. Hazard ratios (HRs), with corresponding 95% confidence intervals (CIs), of VTE were estimated by Cox proportional hazards regression models. During a mean follow-up of 17.8-years, 5241 VTE cases were diagnosed. Compared with individuals in the lowest quartile of the AIDI (score 4), those in the highest quartile (score !8) had a 9% (95% CI, 0e17%) lower risk of VTE. The inverse association was observed in current and past smokers (HR between the two extreme quartiles, 0.80, 95% CI, 0.70e0.91) but not in never smokers (HR, 1.03, 95% CI, 0.91e1.17). French fries (HR per serving, 1.33, 95% CI, 1.06, 1.67) but no other foods included in AIDI was associated with VTE. Conclusion:The study suggests that a consumption of foods with high anti-inflammatory potential may play a role in the prevention of VTE in smokers.

show abstract

Section: Discussionsupporting

confidence: 78%

Anti-inflammatory diet and venous thromboembolism: Two prospective cohort studies

Yuan

Bruzelius

Damrauer

et al. 2021

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

show abstract

“…93–95 Collectively, these results suggest that treatments inhibiting platelet activation such as aspirin might be beneficial in the prevention of VTE, although previous studies and trials on aspirin and combinations with anticoagulants offered mixed results. 96 Different antiplatelets, such as more targeted thrombin, PAR1 or PAR4 inhibitors, or intracellular PDE platelet signaling inhibitors like cilostazol, could be worthwhile for further study in VTE prevention.…”

Section: Discussionmentioning

confidence: 99%

Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors

Thibord

Klarin

Brody

et al. 2022

Preprint

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a complex disease with environmental and genetic determinants. We present new cross-ancestry meta-analyzed genome-wide association study (GWAS) results from 30 studies, with replication of novel loci and their characterization through in silico genomic interrogations. In our initial genetic discovery effort that included 55,330 participants with VTE (47,822 European, 6,320 African, and 1,188 Hispanic ancestry), we identified 48 novel associations of which 34 replicated after correction for multiple testing. In our combined discovery-replication analysis (81,669 VTE participants) and ancestry-stratified meta-analyses (European, African and Hispanic), we identified another 44 novel associations, which are new candidate VTE-associated loci requiring replication. In total, across all GWAS meta-analyses, we identified 135 independent genomic loci significantly associated with VTE risk. We also identified 31 novel transcript associations in transcriptome-wide association studies and 8 novel candidate genes with protein QTL Mendelian randomization analyses. In silico interrogations of hemostasis and hematology traits and a large phenome-wide association analysis of the 135 novel GWAS loci provided insights to biological pathways contributing to VTE, indicating that some loci may contribute to VTE through well-characterized coagulation pathways while others provide new data on the role of hematology traits, particularly platelet function. Many of the replicated loci are outside of known or currently hypothesized pathways to thrombosis. In summary, these findings highlight new pathways to thrombosis and provide novel molecules that may be useful in the development of antithrombosis treatments with reduced risk of bleeds.

show abstract

“…Furthermore, aspirin has been used in primary and secondary thromboprophylaxis. 42 This prompted us to the use of cheap alternative (aspirin) as VTE thromboprophylaxis. Further studies are needed to understand the best thromboprophylaxis policy for the local population.…”

Section: Discussionmentioning

confidence: 99%

Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka

Hewamana

Gunasena

Jayasinghe

et al. 2022

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE There is a significant disparity in global cancer care and outcome between countries. Progress in the treatment of symptomatic plasma cell myeloma (PCM) in high-income countries is not seen in low- and middle-income countries. MATERIALS AND METHODS This is was a retrospective cohort study of all patients diagnosed with PCM between May 1, 2013, and September 30, 2021, at the first hemato-oncology center in Sri Lanka. We aimed to provide data on clinicopathologic characteristics, response, and survival estimates. RESULTS A total of 79 patients with PCM received first-line therapy during the study period. The median age was 64 years, and approximately one third (33%) of patients were older than 70 years. There were 42 (53%) males and 37 females. Hypercalcemia, renal impairment, anemia, and bone disease were detected in 36.7%, 38%, 72.1%, and 81%, respectively. Thirty-nine, 34, and six patients received a combination of cyclophosphamide, thalidomide, and dexamethasone; bortezomib, thalidomide, and dexamethasone; and other treatments, respectively. The overall response rate (≥ partial response) was approximately 97% for both cyclophosphamide, thalidomide, and dexamethasone and bortezomib, thalidomide, and dexamethasone. Twenty-three (29%) of these patients died during the study period, but only 14 (18%) died due to PCM or associated sepsis. After a median follow-up of 40.6 months (range, 35.2-59.07 months), the median overall survival was 84.2 months (95% CI, 60.87 to not available). The 5-year estimated overall survival was 65%. CONCLUSION To our knowledge, this is the only well-characterized study on long-term survival of patients with PCM in Sri Lanka. We have shown that it is possible to successfully apply Western treatment and supportive care protocols to the local population. These published data will help to benchmark and improve the treatment and develop blood cancer care in the local setting.

show abstract

Does aspirin prevent venous thromboembolism?

Cited by 24 publications

References 56 publications

Anti-inflammatory diet and venous thromboembolism: Two prospective cohort studies

Anti-inflammatory diet and venous thromboembolism: Two prospective cohort studies

Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors

Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka

Contact Info

Product

Resources

About